Want to see MOLN full AI Analyst Report?
Top Page
Molecular Partners
(NASDAQ:MOLN)
Select Model
Select Model
Rating:48Neutral
Price Target:
$4.50
▲(1.12% Upside)
Action:Reiterated
Date:08/28/26
The score is held down primarily by weak financial performance (post-2022 losses, volatile/limited revenue, and persistent cash burn), with low leverage offering only partial support. Technicals provide a modest lift due to price strength above key moving averages and a positive MACD, but overbought readings (RSI and Stoch) add near-term risk. Valuation remains challenged because earnings are negative (negative P/E) and no dividend yield is available.
Positive Factors
Cash runway supports continued development
The cash balance and projected runway provide funding visibility for advancing clinical programs without immediate financing pressure, giving management time to generate development data and pursue partnerships.
Negative Factors
No current revenue and persistent losses
The absence of recurring revenue leaves the company dependent on intermittent licensing or milestone income, while sustained losses limit financial self-sufficiency and increase reliance on future asset or partnership success.
Read all positive and negative factors
Positive Factors
Negative Factors
Cash runway supports continued development
The cash balance and projected runway provide funding visibility for advancing clinical programs without immediate financing pressure, giving management time to generate development data and pursue partnerships.
Read all positive factors
Molecular Partners (MOLN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$181.07M
Dividend YieldN/A
Average Volume (3M)2.31K
Price to Earnings (P/E)―
Beta (1Y)0.61
Revenue Growth-100.00%
EPS Growth17.74%
CountryUS
Employees134
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.35
Shares Outstanding40,374,640
10 Day Avg. Volume2,377
30 Day Avg. Volume2,311
Financial Highlights & Ratios
PEG Ratio-0.56
Price to Book (P/B)1.60
Price to Sales (P/S)0.00
P/FCF Ratio-2.48
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$12.50Price Target Upside180.90% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.78
Revenue Forecast (FY)N/A
Molecular Partners Business Overview & Revenue Model
Company Description
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, specializing in the identification, advancement, and commercialization of innovative therapeutic proteins. The firm's pipeline includes a range of product candidates, ma...
How the Company Makes Money
Molecular Partners primarily makes money through a partnering/licensing-driven biopharmaceutical model rather than through large-scale sales of approved products. Its revenue is generally generated from (1) collaboration and license agreements wit...
Molecular Partners Earnings Call Summary
Earnings Call Date:Mar 06, 2025
(Q4-2024)
| % Change Since: |
Next Earnings Date:Mar 18, 2027
Earnings Call Sentiment Positive
The earnings call highlighted significant progress in Molecular Partners' programs, particularly in the radio DARPin franchise and the improved efficacy of the 533-DARPIn program. The expansion of the Orano Med collaboration and strong financial position further bolster the company's outlook. However, the discontinuation of the Novartis collaboration and initial challenges with the T Cell Engager program were noted as setbacks. Overall, the highlights significantly outweigh the lowlights.Positive Updates
Successful Year of Execution
Molecular Partners successfully executed their plans in 2024, advancing programs toward clinical readouts and expanding their collaboration with Orano Med.
Negative Updates
Discontinuation of Novartis Collaboration
The collaboration with Novartis was discontinued after three years due to lack of strategic interest in the research targets.
Read all updates
Q4-2024 Updates
Positive
Negative
Successful Year of Execution
Molecular Partners successfully executed their plans in 2024, advancing programs toward clinical readouts and expanding their collaboration with Orano Med.
Read all positive updates
Company Guidance
During the Molecular Partners Fourth Quarter and Full Year 2024 Results Call, several key metrics and strategic developments were highlighted. The company reported operating expenses of CHF 66 million for the year, which was within their guidance range of CHF 65 million to CHF 70 million. They ended the year with a cash balance of CHF 149 million, having raised CHF 20 million in a financing round in October, and reported a cash burn of approximately CHF 54 million for the year. This funding positions them well financially, with a runway extending into 2027. Revenue for 2024 was CHF 5 million, primarily from their collaboration with Novartis, which has now concluded. The company is advancing its radio DARPin program, with their lead candidate MP0712 set to begin clinical trials and dosimetry studies in 2025. The expansion of their collaboration with Orano Med was also a significant milestone, securing access to 10 product slots for the promising isotope Lead-212. Additionally, Molecular Partners is continuing to refine its T cell engager platform, with plans to densify dosing schedules and further investigate premedication strategies in upcoming trials.Molecular Partners Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
54
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 4.97M | 7.04M | 189.56M | 9.33M |
| Gross Profit | -2.30M | -2.58M | -42.53M | -40.81M | 138.81M | -46.39M |
| EBITDA | -55.42M | -59.49M | -51.65M | -59.52M | 119.00M | -60.66M |
| Net Income | -57.55M | -61.65M | -54.04M | -61.98M | 117.85M | -63.78M |
Balance Sheet | ||||||
| Total Assets | 75.43M | 102.11M | 158.53M | 198.35M | 262.26M | 172.67M |
| Cash, Cash Equivalents and Short-Term Investments | 67.69M | 93.06M | 149.44M | 186.89M | 249.14M | 132.81M |
| Total Debt | 3.03M | 3.64M | 2.44M | 3.65M | 4.85M | 6.04M |
| Total Liabilities | 17.09M | 21.77M | 16.89M | 21.92M | 27.09M | 65.38M |
| Stockholders Equity | 58.34M | 80.33M | 141.64M | 176.43M | 235.17M | 107.29M |
Cash Flow | ||||||
| Free Cash Flow | -51.77M | -51.97M | -59.97M | -59.81M | 117.15M | -92.26M |
| Operating Cash Flow | -51.51M | -51.26M | -59.25M | -59.01M | 118.57M | -90.95M |
| Investing Cash Flow | 39.70M | 72.55M | 40.49M | 44.64M | -101.12M | -22.24M |
| Financing Cash Flow | -1.28M | -1.15M | 14.43M | -1.17M | -1.57M | 50.58M |
Molecular Partners Technical Analysis
Positive
4.45
Price Trends
4.09
Positive
4.09
Positive
4.24
Positive
Market Momentum
0.12
Negative
55.78
Neutral
71.48
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MOLN, the sentiment is Positive. The current price of 4.45 is above the 20-day moving average (MA) of 4.27, above the 50-day MA of 4.09, and above the 200-day MA of 4.24, indicating a bullish trend. The MACD of 0.12 indicates Negative momentum. The RSI at 55.78 is Neutral, neither overbought nor oversold. The STOCH value of 71.48 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MOLN.
Molecular Partners Risk Analysis
Molecular Partners disclosed 102 risk factors in its most recent earnings report. Molecular Partners reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Molecular Partners Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $246.29M | 6.82 | 42.57% | ― | 234.18% | ― | |
56 Neutral | $706.56M | -13.75 | -43.57% | ― | -66.63% | 57.89% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $181.07M | -2.63 | -66.19% | ― | -100.00% | 17.74% | |
48 Neutral | $473.65M | -3.71 | -45.45% | ― | 2.33% | 36.86% | |
44 Neutral | $197.68M | -1.73 | -39.64% | ― | ― | -6.70% | |
42 Neutral | $109.23M | -3.38 | 1020.21% | ― | ― | 2.05% |
* Healthcare Sector Average
MOLN
Molecular Partners
4.38
0.58
15.26%
CGEN
Compugen
2.56
1.13
79.02%
ONCY
Oncolytics Biotech
0.84
-0.31
-27.13%
NKTX
Nkarta
2.71
0.61
29.05%
CCCC
C4 Therapeutics
3.71
1.20
47.81%
STTK
Shattuck Labs
7.01
6.00
594.06%
Molecular Partners Corporate Events
Molecular Partners Advances DLL3 Radio-DARPin MP0712 and Expands Alpha Therapy Pipeline on Solid H1 2026 Cash Base
Aug 25, 2026
Molecular Partners reported its first-half 2026 results and corporate developments on August 25, 2026, highlighting progress across its DARPin-based oncology pipeline and a solid cash position. The company ended June 30, 2026 with CHF 67.9 million...
Molecular Partners Starts Phase 2 TACTIC Trial of MP0317 in Front-Line Cholangiocarcinoma
Jul 20, 2026
On July 16, 2026, Molecular Partners announced the first patients have been dosed in the investigator-initiated Phase 2 TACTIC proof-of-concept trial evaluating MP0317 in combination with chemoimmunotherapy for front-line treatment of advanced bil...
Molecular Partners Advances Radio-DARPin Cancer Pipeline With MP0712 Trial and Upcoming MP0726 Imaging
Jul 7, 2026
On July 6, 2026, Molecular Partners reported clinical progress across its expanding pipeline of Radio-DARPin therapeutics targeting cancers with high unmet need. The Phase 1/2a U.S. trial of MP0712, a DLL3-targeted, 212Pb-based Radio-DARPin for sm...
Molecular Partners and Orano Med Dose First Patients in MP0712 Phase 1/2a Trial
Jul 2, 2026
On July 2, 2026, Molecular Partners and Orano Med reported that the first patients have been dosed in a U.S. multicenter Phase 1/2a trial of MP0712, a DLL3-targeting Radio-DARPin carrying a lead‑212 payload. The program, conducted at five ac...
Molecular Partners Starts Dosing DLL3 Radio-DARPin MP0712, Highlights Program at ASCO and SNMMI 2026
Jun 1, 2026
On May 30, 2026, Molecular Partners announced it is presenting trial-in-progress data on its DLL3-targeting Radio-DARPin MP0712 at the ASCO and SNMMI 2026 meetings, as the U.S. multicenter Phase 1/2a study begins dosing and actively recruits patie...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.